.svg){kind=small}
Apr-2026
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Avexia has demonstrated a consistent performance in the Illinois market, particularly in the Capsules and Topical categories. In Illinois, Avexia maintained a stronghold in the Topical category, consistently ranking first from January to April 2026, with sales peaking in April. The Capsules category also showed stability, holding the second position throughout the same period. However, a notable dip in sales was observed in April for Capsules, which could be an area of concern. In the Concentrates category, Avexia improved its position from 28th in January to 22nd by April, indicating a positive trend despite not having been in the top 20 initially.
In Maryland, Avexia's performance in the Topical category remained robust, maintaining the first position in three out of the four months. The Capsules category also showed strong results, consistently ranking second from February to April. However, Avexia's presence in the Concentrates category was inconsistent, missing the top 30 in February and April, which highlights a potential area for growth. Meanwhile, in New Jersey, Avexia displayed a stable ranking in the Tincture & Sublingual category, consistently holding the third position. The Topical category also saw Avexia leading the market, maintaining the first position throughout the months. In Ohio, Avexia showed a strong presence in Capsules and Tincture & Sublingual categories, although it only entered the top 30 for Concentrates in April, suggesting an opportunity to strengthen its market position further.
Competitive Landscape
In the Illinois Topical category, Avexia has consistently maintained its position as the leading brand from January to April 2026, demonstrating a strong hold on the market. This consistent top ranking is indicative of Avexia's robust brand presence and customer loyalty in the region. While Doctor Solomon's has shown some fluctuations, moving from second to third place in February before returning to second, it remains a significant competitor, albeit with sales figures substantially lower than Avexia's. Meanwhile, Alchemy (Ieso) has maintained a steady fourth-place rank throughout the same period, indicating a stable but less competitive position compared to Avexia. The consistent top ranking of Avexia suggests a strong market strategy and product appeal, which competitors have yet to match in terms of both rank and sales growth.
Notable Products
In April 2026, Avexia's top-performing product was the CBD/THC 1:1 Harmony Pain Relief Balm (100mg CBD, 100mg THC, 2oz) in the Topical category, maintaining its number one rank for the fourth consecutive month with sales reaching 8730. The CBD/THC 4:1 Relief Tablets 40-Pack (400mg CBD, 100mg THC) consistently held the second position, showing steady improvement in sales figures. The CBN/CBD/THC 1:1:1 Comfort Tablets 40-Pack (100mg CBN, 100mg CBD, 100mg THC) remained third, despite a slight decline in sales. The CBD/THC 1:1 Harmony Micro-Dosed Tablets 40-Pack (100mg CBD,100mg THC) continued to rank fourth, maintaining its position from previous months. Notably, the CBD/THC 1:1 Harmony Pain Relief Lotion (100mg CBD, 100mg THC, 2oz) entered the rankings at fifth place, marking its first appearance in the top five.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
